Author: Ravi Shankar

• Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. 
• Vamorolone has already received South Korean Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation. 
• Targeting regulatory approval in South Korea in 2027 and commercial launch in 2028. 

Tokyo, Japan and Cambridge, UK, 22 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has submitted a Marketing Authorization Application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). 

As announced on 2 June 2026, vamorolone has received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation in South Korea. GIFT is a priority review pathway designed to accelerate the review of innovative medicines targeting life-threatening or serious diseases, including rare diseases, and is expected to help shorten the review timeline and support earlier patient access to vamorolone. The Company is targeting marketing authorization in South Korea in 2027, followed by a commercial launch in 2028. 

In January 2026, Nxera acquired exclusive rights from Santhera Pharmaceuticals Holding (“Santhera”) to develop, manufacture and commercialize vamorolone in Japan, South Korea, Australia and New Zealand. Nxera is leading regulatory approval, commercialization and manufacturing activities in these territories. Vamorolone is a dissociative corticosteroid developed to preserve anti-inflammatory efficacy while reducing the systemic side effects associated with long-term conventional corticosteroid therapy. It is approved and marketed for the treatment of DMD in the US, European Union, UK and China. 

Mr. MinBok Lee, President and Representative Director of Nxera Pharma Korea, commented: ” This submission marks an important milestone towards bringing a new treatment option to patients with DMD and their families in South Korea. Following the ODD and GIFT designations, we are very pleased to have reached this submission milestone as planned. DMD is a serious, progressive disease requiring long-term treatment, and we believe vamorolone has the potential to address an important unmet medical need by offering a differentiated treatment option with a more favorable long-term safety profile. We will continue to explore ways to bring vamorolone to Korean patients sooner, while working closely with the regulatory authorities towards approval.”  

About Duchenne Muscular Dystrophy  

Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of self-feeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD typically reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure.  

About vamorolone  

Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). It binds selectively to the glucocorticoid receptor and triggers anti-inflammatory activity through inhibition of NF‑κB-mediated gene transcription, while inducing reduced transactivation of other genes [1]. Vamorolone is not a substrate for 11‑β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, which are involved in the local amplification of glucocorticoid activity in tissues and have been implicated in corticosteroid-associated toxicity [2,3]. This pharmacological profile is the basis for its classification as a dissociative corticosteroid, designed to preserve anti-inflammatory efficacy while reducing the systemic effects associated with long-term conventional corticosteroid therapy [1–3].  

In the pivotal Phase 2b VISION-DMD study, vamorolone met its primary endpoint, demonstrating a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo at 24 weeks (p = 0.002) [4]. The most commonly reported adverse reactions were cushingoid features, vomiting, weight increase, increased appetite, and irritability; most were mild to moderate in severity [1]. 

Long-term data from up to eight years of vamorolone treatment were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2026[5,6]. In propensity-matched analyses, vamorolone demonstrated durable efficacy comparable to standard-of-care corticosteroids and a differentiated safety profile: a lower incidence of vertebral fractures versus deflazacort-treated cohorts (8.1% vs 41.9%; p = 0.0082) [5]; maintained normal growth trajectory with a mean height advantage of 12.17 cm versus conventional corticosteroids (p < 0.0001) [5,6], and a lower incidence of cataracts versus deflazacort (p = 0.015), with no observed cases of glaucoma [5]. 

References 

[1] AGAMREE® (vamorolone) Summary of Product Characteristics. European Medicines Agency; authorised 14 December 2023. 

[2] Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. Life Sci Alliance. 2019;2(1): e201800186. 

[3] Reeves EKM, Hoffman EP, Nagaraju K, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013; 21(8): 2241–2249. 

[4] Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy (VISION-DMD). Neurology. 2024;102(5): e208112. 

[5] Guglieri M, et al. Long-term impact of vamorolone on bone health compared to standard of care glucocorticoids in boys with Duchenne muscular dystrophy. Poster 62S, MDA Clinical & Scientific Conference 2026. 

[6] McDonald CM, et al. Comparative analysis of long-term effectiveness of vamorolone versus standard of care glucocorticoid treatment in boys with Duchenne muscular dystrophy. Poster 23S, MDA Clinical & Scientific Conference 2026. 

–END– 

About Nxera Pharma 

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). 

For more information, please visit www.nxera.life  

LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma 

Enquiries: 

Nxera – Media and Investor Relations 

Shinya Tsuzuki, VP, Head of Investor Relations 

+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life  

MEDiSTRAVA (for International Media) 

Mark Swallow, Frazer Hall, Erica Hollingsworth 

+44 (0)203 928 6900 | Nxera@medistrava.com  

Forward-looking statements 

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Company advances plans for Chicago-area graphene production facility targeting initial capacity of 10 metric tonnes per quarter, alongside encouraging preliminary lubricant testing results

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Argo Graphene Solutions Corp. (CSE: ARGO | OTCQB: ARLSF | FSE: 94Y) (“Argo” or the “Company”) is pleased to provide an update on its plans to establish a commercial-scale graphene refinery in the Chicago, Illinois area, while reporting encouraging preliminary results from its evaluation of graphene as a performance-enhancing additive in industrial lubricants.

Together, these initiatives advance Argo’s strategy to build a vertically integrated graphene business, connecting commercial-scale production with the development of graphene-based products for industrial markets.

Argo’s commercialization strategy is built around its exclusive worldwide licence to Grapherry’s proprietary STREAM™ production technology. The agreement also establishes a contractual pathway to full ownership, supporting Argo’s long-term objective of owning its core production technology.

Advancing Argo’s Graphene Refinery Strategy

Argo continues to advance its plans to establish a commercial-scale graphene refinery in the Chicago area, representing an important step in the Company’s transition from pilot-scale production toward commercial manufacturing.

The Company is in the final stages of securing a facility intended to house its STREAM™ production operations, supporting the manufacture of graphene and graphene oxide for a broad range of industrial applications.

A wholly owned Nevada-incorporated subsidiary of Argo Graphene Solutions Corp. has been granted Authority to Transact Business in Illinois by the Illinois Secretary of State, effective October 15, 2026. The subsidiary is undergoing a corporate name change to better reflect Argo’s expanding portfolio of graphene and graphene oxide products and industrial applications. The Company will announce the new name following regulatory approval.

Argo’s initial development phase targets production capacity of approximately 10 metric tonnes of graphene per quarter, with plans to expand to approximately 90 metric tonnes per quarter as the Company advances its longer-term commercialization strategy.

Argo also plans to expand its graphene oxide production capabilities, initially targeting 30 metric tonnes per quarter of graphene oxide dispersion at a 20% concentration, with further capacity expansion contemplated as commercial operations develop.

The proposed facility is intended to support Argo’s vertically integrated refinery model, combining graphene production with material testing, application development and customer qualification programs.

Following the completion of its C$1.47 million financing in September 2026, Argo intends to advance facility development, production scale-up and customer qualification programs. The planned refinery is expected to support the development of graphene and graphene oxide products for industrial markets, including construction, energy storage, composites, coatings and lubricants, while providing a foundation for future commercial partnerships.

Expanding Industrial Applications: Graphene-Enhanced Lubricants

Alongside its refinery development, Argo is advancing its evaluation of graphene-enhanced industrial lubricants, representing another potential commercial application for its graphene technology.

Preliminary testing has produced encouraging results, demonstrating that graphene remained dispersed in a specially formulated mineral oil for multiple weeks at tested concentrations ranging from 0.05% to 0.50% by weight. Maintaining stable dispersion is an important step toward developing lubricant formulations with the potential to reduce friction, minimize equipment wear and improve operating efficiency. Initial friction testing has also yielded encouraging observations, supporting further performance evaluation and formulation development.

The global lubricants industry represents a substantial market for potential performance-enhancing additives. According to Grand View Research, the global lubricants market is projected to reach approximately US$155 billion in 2026, growing to more than US$204 billion by 2033. Graphene-based additives could potentially enhance existing lubricant formulations across industries including transportation, manufacturing, construction, mining and energy.

Argo intends to continue testing and refining its formulations, with a focus on validating performance improvements and identifying commercially viable applications.

“Our planned Chicago-area refinery is a key step in building the production capabilities needed to commercialize graphene across multiple industrial markets,” said Dr. Vikas Berry, CEO of Argo Graphene Solutions Corp. “The encouraging results from our preliminary lubricant testing highlight another potential application for graphene. Our focus is on advancing production, validating performance and translating these opportunities into commercial products.”

About Argo Graphene Solutions Corp.

Argo Graphene Solutions Corp. is a Canadian advanced materials company developing and commercializing graphene technologies based on the proprietary STREAM™ production platform, exclusively licensed from Grapherry with a pathway to full ownership. Led by CEO Dr. Vikas Berry, Argo is developing a vertically integrated graphene refinery platform designed to connect graphene and graphene oxide production with application development, industrial testing and commercialization.

The Company is evaluating STREAM™ materials across multiple industrial markets, including energy storage, AI infrastructure, semiconductors and advanced electronics, construction, composites, agriculture, coatings and other emerging applications. Argo’s strategy combines advanced-material production, application development, testing, industry collaboration and commercialization.

We seek Safe Harbor.

For further information please contact:
Robert Intile, CFO
Argo Graphene Solutions Corp.
Email: robert.intile@argographene.com
Phone: 604-763-4017
Website: www.argographene.com
Social Media: LinkedIn | Instagram | Facebook | X / Twitter

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will”, “plans”, or variations of such words or phrases. Forward-looking information includes, but is not limited to: statements regarding the transfer of the STREAM™ technology and related intellectual property to the Company; the Company’s anticipated development, manufacture and commercialization of the Stream™ technology and graphene-enhanced products. Forward-looking information is based on assumptions considered reasonable by management as of the date of this news release. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. Forward-looking information speaks only as of the date hereof, and the Company undertakes no obligation to update or revise such information except as required by applicable securities laws.

GRAND CAYMAN, Cayman Islands, Oct. 22, 2026 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (Nasdaq: GLRE) (“Greenlight Re” or the “Company”) announced today that Greenlight Innovation Syndicate 3456 (“Syndicate 3456”) has appointed Ian Maguire as Active Underwriter, subject to regulatory approval, as Syndicate 3456 transitions from a Syndicate-in-a-Box to a full Lloyd’s syndicate with effect from January 1, 2027.

Syndicate 3456, which writes Greenlight Re Innovations business with a focus on Coverholder partnerships, began underwriting as a Syndicate-in-a-Box on April 1, 2022, with the support of third-party managing agent Asta. The transition to a full syndicate will allow Syndicate 3456 to continue to support innovative Coverholders as well as more traditional Coverholder business, with strong growth anticipated in 2027.

Greg Richardson, Greenlight Re CEO, said:

“Ian has been assisting Syndicate 3456 as a consultant over the last six months, and we are delighted that Ian is now joining Syndicate 3456, as Active Underwriter, at this significant time in the evolution of Syndicate 3456. Ian’s nearly 40 years of experience in the Lloyd’s and London markets, including as Active Underwriter of a major Lloyd’s syndicate with specific expertise in managing delegated authority books of business, will be invaluable as we transition to a full syndicate. While Innovations business will remain the primary focus of Syndicate 3456, we plan to expand our offering to include some more traditional delegated underwriting authority and consortia business, as well as a limited amount of treaty reinsurance. Ian’s appointment highlights the investment we are making in our Lloyd’s platform, which is a key part of our overall strategy.”

Ian Maguire, Active Underwriter, Syndicate 3456 added:

“I am excited to be joining Syndicate 3456 as it transitions to a full syndicate effective January 1, 2027. Having worked with the team in recent months, I have seen first-hand the quality of the underwriting platform and the attractive and diverse portfolio of Innovations business that Syndicate 3456 has developed. Broadening our underwriting appetite is an area where I look forward to applying my experience as Syndicate 3456 grows and establishes itself further in the market.”

About Ian Maguire

Ian Maguire brings nearly 40 years of distinguished Lloyd’s and London market insurance experience. He previously served as Executive Director of Argenta Holdings and, from 2011 to 2021, as Active Underwriter of Argenta Syndicate 2121. During his tenure at Argenta, he managed the syndicate’s property direct and facultative account and oversaw the development of its other, predominantly short-tail, classes of business. Prior to joining Argenta in 2004, Mr. Maguire was responsible for North American direct property facility business at Wellington Underwriting.

About Greenlight Capital Re, Ltd.

Greenlight Re (www.greenlightre.com) provides multiline property and casualty insurance and reinsurance through its licensed and regulated reinsurance entities in the Cayman Islands and Ireland, and its Lloyd’s platform, Greenlight Innovation Syndicate 3456. The Company complements its underwriting activities with a non-traditional investment approach designed to achieve higher rates of return over the long term than reinsurance companies that exclusively employ more traditional investment strategies. The Company’s innovations unit, Greenlight Re Innovations, supports technology innovators in the (re)insurance space by providing investment capital, risk capacity, and access to a broad insurance network.

Forward Looking Statements

This news release contains forward-looking statements concerning Greenlight Capital Re, Ltd. and/or its subsidiaries within the meaning of the U.S. federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements made on the Company’s behalf. These risks and uncertainties include the impact of general economic conditions and conditions affecting the insurance and reinsurance industry, the timing and outcome of any regulatory approvals, our ability to retain and integrate key personnel, adequacy of our reserves, our ability to assess underwriting risk, trends in rates for property and casualty insurance and reinsurance, competition, investment market fluctuations, trends in insured and paid losses, catastrophes, regulatory and legal uncertainties, and other factors described in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as those factors may be updated from time to time in our periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, which speak only as to the date of this release, whether as a result of new information, future events, or otherwise, except as provided by law.

Investor Relations Contact

Jeremy Hellman
Vice President, The Equity Group Inc.
(212) 836-9626
IR@greenlightre.ky

Serstech has appointed Carl Vilhelm Crona as CCO, effective immediately. Carl has been part of Serstech’s sales team for more than a year and will now assume overall responsibility for the company’s sales organization globally.

Carl brings more than 20 years of experience in International Sales and Sales Management, including 15 years in the Security industry. His extensive professional experience is complemented by academic studies in Business Administration and Communication at Linnaeus University and Malmö University in Sweden.

“Serstech is entering an exciting phase of growth. With his extensive international experience, strong industry expertise and leadership skills, Carl will play a key role in developing our sales strategy and accelerating our growth,” says Stefan Sandor, CEO of Serstech.

For further information, please contact:

Stefan Sandor,

CEO, Serstech AB Phone: +46 739 606 067

Email: ss@serstech.com

or

Arve Nilsson,

Chairman of the Board, Serstech AB Phone: +45 40 35 82 65

Email: arve.nilsson@serstech.com

or visit: www.serstech.com

Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG).

About Serstech

Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden.

Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com

Vilnius, Lithuania, Oct. 22, 2026 (GLOBE NEWSWIRE) —

UAB Janonio 27, a company managed by the investment company AB Tewox, has successfully completed the construction of a grocery store located at J. Janonio St. 27, Klaipeda. The total investment in the project amounts to approximately EUR 6.5 million.

The property is leased on a long-term basis to the supermarket chain Lidl, which starts operations in the newly developed premises on 22 October 2026. The total leasable area is approximately 2,100 sq. m.

One additional store will be built in Lithuania in 2026. In total, more than 10,000 sq. m of leasable area will be developed this year.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

New FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections, eliminating the need to disconnect multiple fibres to gain access

Eindhoven, Netherlands, Oct. 22, 2026 (GLOBE NEWSWIRE) — As AI, cloud and high-speed networking drive higher fibre density in data centres, technicians installing or troubleshooting fibre connections need to inspect connector end faces hidden within densely populated patch panels. The process increases troubleshooting time, operational complexity and the risk of network disruption. To address these challenges, Fluke Networks today announced new inspection tips for the FI-3000 FiberInspector™ Pro, enabling access to MMC fibre connections in high-density environments without disturbing critical network infrastructure.

The new portfolio consists of two MMCE extended-reach inspection tips, available in keyed and keyless versions, that eliminate one of the most common challenges in high-density data centres: accessing fibre connectors for inspection without disturbing active infrastructure. The tips provide direct access to bulkhead connectors and patch panel ports from the front of the rack, reducing the need to disconnect multiple fibre assemblies while accelerating troubleshooting and helping protect network uptime.

Contaminated fibre remains one of the leading causes of optical network performance issues. In an NTT-Advanced Technology study, 96% of installers and 80% of network operators reported problems related to connector end-face contamination. As connector density increases, so does the challenge of inspecting and maintaining fibre connections. Multi-fibre connectors create more opportunities for contamination while making access and inspection more difficult. The new MMC inspection tips help technicians follow fibre inspection best practices, inspect hard-to-reach connectors and maintain fibre quality without adding workflow complexity.

“The industry’s push toward greater fibre density is transforming data centre infrastructure, but it’s also creating new challenges for the teams responsible for keeping networks running reliably,” said Mark Mullins, Global Product Manager, Fluke Networks. “Technicians shouldn’t have to disrupt installed infrastructure just to inspect a fibre connection. With these new FI-3000 inspection tips, we’re removing a longstanding operational tradeoff by enabling access to hard-to-reach MMC connectors from the front of the rack. That means faster installation and troubleshooting, less complexity and greater confidence that critical networks remain online and performing as expected.”

Together, the new inspection tips help reduce the operational burden associated with maintaining and troubleshooting fibre infrastructure. Rather than disconnecting adjacent connections to gain access or spending time locating the correct fibre from the back of a rack, technicians can inspect connectors directly through the front of populated patch panels. This streamlined workflow helps accelerate commissioning, troubleshooting and routine maintenance activities.

The MMC tips are designed for use with the FI-3000 FiberInspector Ultra, part of Versiv™, the industry’s leading Cabling Certification platform, which also supports twisted pair cabling along with single-and multifibre connections.  Contractors using the platform report minimal training time and Fluke offers factory-certified training with over 10,000 certified technicians worldwide. Documentation of results is offered through LinkWare™, the most widely accepted reporting software with nearly 40,000 downloads and nearly 200 million results stored.

To learn more about the new MMC inspection tips for the FI-3000 FiberInspector Pro and how they simplify inspection of critical fibre connections in high-density data centre environments, please visit FI-3000 FiberInspector Pro MMC Inspection Tips.

About Fluke
Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measurement and condition monitoring. Fluke customers include technicians, engineers, electricians, maintenance managers and metrologists who install, troubleshoot and maintain industrial, electrical and electronic equipment and calibration processes.

###

FLUKE is a registered trademark of Fluke Corporation. For more information, visit www.fluke.com.

Media Contacts:
Dave Smith
Fluke Corporation
dave.smith@fluke.com

Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

Q: What is the FI-3000 FiberInspector™ Pro?
A: The FI-3000 FiberInspector™ Pro is a fiber inspection solution that helps technicians identify contamination and defects on fibre connector end faces before they impact network performance, reliability or certification results. Automated pass/fail analysis and interchangeable inspection tips enable fast, consistent inspection across a wide range of fiber connector types.

Q: What challenges are the new FI-3000 FiberInspector™ Pro tips designed to address?
A: As data centres increase fiber density to support AI, cloud and high-speed networking, technicians often have to disconnect multiple fibre connections or work through crowded racks to access connectors for inspection. The new inspection tips provide direct access to hard-to-reach MMC connectors, reducing complexity, troubleshooting time and the risk of network disruption.

Q: What benefits do the new FI-3000 inspection tips deliver to customers?
A: The new tips make it easier to inspect critical fibre connections without disconnecting active infrastructure. Customers can accelerate maintenance and troubleshooting, improve adherence to fibre inspection best practices, maintain fibre quality and help protect network reliability and uptime.

 

Attachments

• New Fluke FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections
• New Fluke FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections

CONTACT: Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND

Information about securities repurchasing program
Regulated information
Issuer social denomination: Michelin – LEI 549300SOSI58J6VIW052
Types of securities: ordinary shares – Code ISIN FR001400AJ45
Date : October 22nd, 2026

Issuer Name	Issuer code	Transaction date	ISIN Code	Daily total volume (in number of actions)	Daily weighted average price of shares acquired	Platform
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter

Issuer Name	Issuer code	PSI Name	Issuer Code	Transaction date	ISIN Code	Unit Price	Currency	Quantity bought	Platform	Transaction reference number	Buyback objective
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	NATIXIS	KX1WK48MPD4Y2NCUIZ63	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	BNP PARIBAS	R0MUWSFPU8MPRO8K5P83	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	SOCIETE GENERALE	O2RNE8IBXP4R0TD8PU41	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation

Attachment

• 20261022 – Disclosure of trading in own shares – October 22nd, 2026

Winterthur, Switzerland / Shenyang, China, 22. October 2026 – Shenyang Yuanda Compressor Co., Ltd. (SYCC), a subsidiary of Burckhardt Compression, has secured several orders for diaphragm compressor units supporting hydrogen applications in the semiconductor industry. The projects will serve semiconductor manufacturing facilities in Taiwan and Korea through a leading global industrial gas supplier.

The compressor units will boost hydrogen pressure downstream of a purification system, enabling the reliable delivery of ultra-high-purity hydrogen required for advanced semiconductor manufacturing processes.

Hydrogen plays a critical role in semiconductor production. It is used in key manufacturing steps such as epitaxial growth, annealing, deposition and advanced lithography processes, helping chip manufacturers maintain the extremely high levels of purity and precision required for today’s semiconductors.

Driven by continued investments in artificial intelligence, data centers, advanced electronics and digital infrastructure, semiconductor manufacturers around the world are expanding production capacity. This growth is increasing demand for ultra-high-purity process gases and the associated compression technologies required throughout the semiconductor value chain.

Leveraging Burckhardt Compression’s proven piston and gas-tight diaphragm compressor technologies, SYCC provides robust hydrogen compression solutions, designed to meet the stringent purity, safety and reliability requirements of semiconductor manufacturing facilities.

These orders further strengthen Burckhardt Compression’s position in hydrogen compression and provide an entry into a new market for the company, based on its existing technology portfolio.

CHICAGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Marquette National Corporation (OTCQX: MNAT) today announced that its Board of Directors declared a cash dividend of $0.33 per share. The dividend will be payable on January 4, 2027 to shareholders of record on December 18, 2026. As of September 30, 2026, Marquette had 4,388,274 shares issued and outstanding.  

The Company also announced that its Board of Directors authorized the repurchase of up to $1,000,000 of its outstanding common stock at prevailing market prices through open market or negotiated transactions. The repurchase program is authorized from January 1, 2027 through December 31, 2027. The Company’s previously announced Repurchase Program will terminate on December 31, 2026.

Marquette National Corporation is a diversified bank holding company with total assets of $2.1 billion. The Company’s banking subsidiary, Marquette Bank, is a full-service, community bank that serves the financial needs of communities in Chicagoland, offering an extensive line of financial solutions, including retail banking, real estate lending, trust, insurance, investments, wealth management and business banking to consumers and commercial customers. Marquette Bank has 20 branches located in: Chicago, Bolingbrook, Bridgeview, Evergreen Park, Hickory Hills, Lemont, New Lenox, Oak Forest, Oak Lawn, Orland Park, Summit and Tinley Park, Illinois. For more information visit: https://emarquettebank.com

Special Note Concerning Forward-Looking Statements
This document contains, and future oral and written statements of the Company and its management may contain, forward-looking statements with respect to the financial condition, results of operations, plans, objectives, future performance and business of the Company. Forward-looking statements, which may be based upon beliefs, expectations and assumptions of the Company’s management and on information currently available to management, are generally identifiable by the use of words such as “believe,” “expect,” “anticipate,” “bode”, “predict,” “suggest,” “project”, “appear,” “plan,” “intend,” “estimate,” ”annualize,” “may,” “will,” “would,” “could,” “should,” “likely,” “might,” “potential,” “continue,” “annualized,” “target,” “outlook,” as well as the negative forms of those words, or other similar expressions. Additionally, all statements in this document, including forward-looking statements, speak only as of the date they are made, and the Company undertakes no obligation to update any statement in light of new information or future events. A number of factors, many of which are beyond the ability of the Company to control or predict, could cause actual results to differ materially from those in its forward-looking statements. These factors include, but are not limited to: (i) the strength of the local, state, national and international economies and financial markets (including effects of inflationary pressures); (ii) effects on the U.S. economy resulting from actions taken by the federal government, including the threat or implementation of tariffs, immigration enforcement, and changes in foreign policy and tax regulations; (iii) the economic impact of any future terrorist threats and attacks, widespread disease or pandemics, military conflicts, acts of war or threats thereof (including the Russian invasion of Ukraine, ongoing conflicts in the Middle East and the recent military actions in Venezuela), or other adverse events that could cause economic deterioration or instability in credit markets, and the response of the local, state and national governments to any such adverse external events; (iv) new or revised accounting policies and practices, as may be adopted by state and federal regulatory agencies, the Financial Accounting Standards Board or the Public Company Accounting Oversight Board; (v) changes in local, state and federal laws, regulations and governmental policies concerning the Company’s general business; (vi) the imposition of tariffs or other governmental policies impacting the value of products produced by the Company’s commercial borrowers; (vii) increased competition in the financial services sector, including from non-bank competitors such as credit unions and fintech companies, and the inability to attract new customers; (viii) changes in technology and the ability to develop and maintain secure and reliable electronic systems; (ix) unexpected results of acquisitions which may include failure to realize the anticipated benefits of the acquisitions and the possibility that transaction costs may be greater than anticipated; (x) the loss of key executives and employees, talent shortages and employee turnover; (xi) changes in consumer spending; (xii) unexpected outcomes and costs of existing or new litigation or other legal proceedings and regulatory actions involving the Company; (xiii) the economic impact on the Company and its customers of climate change, natural disasters and exceptional weather occurrences such as tornadoes, floods and blizzards; (xiv) fluctuations in the value of securities held in our securities portfolio, including as a result of changes in interest rates; (xv) credit risk and risks from concentrations (by type of borrower, geographic area, collateral and industry) within our loan portfolio and large loans to certain borrowers (including CRE loans); (xvi) the overall health of the local and national real estate market; (xvii) the ability to maintain an adequate level of allowance for credit losses on loans; (xviii) the concentration of large deposits from certain clients who have balances above current FDIC insurance limits and who may withdraw deposits to diversify their exposure; (xix) the ability to successfully manage liquidity risk, which may increase dependence on non-core funding sources such as brokered deposits, and may negatively impact the Company’s cost of funds; (xx) the level of non-performing assets on our balance sheets; (xxi) interruptions involving our information technology and communications systems or third-party servicers; (xxii) the occurrence of fraudulent activity, breaches or failures of our third-party vendors’ information security controls or cybersecurity-related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools or as a result of insider fraud; (xxiii) changes in the interest rates and repayment rates of the Company’s assets; (xxiv) the effectiveness of the Company’s risk management framework, and (xxv) the ability of the Company to manage the risks associated with the foregoing as well as anticipated. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

For more information: Patrick Hunt SEVP / CFO 708-364-9019 phunt@emarquettebank.com

SSCP Lager BidCo AB (publ) (“SSCP Lager BidCo” or the “Issuer”), announced on 6 October 2026 that the Issuer is exercising its right to make a conditional voluntary total redemption of its outstanding senior secured floating rate notes 2023/2026 with ISIN SE0021021193 (the “Notes” and the “Redemption”), in accordance with the terms and conditions of the Notes.

The Redemption was conditional upon the successful execution of a facilities agreement with, inter alios, certain lenders and the Issuer being content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on 30 October 2026, which is the date of the Redemption (the “Redemption Date” and the “Condition”).

SSCP Lager BidCo today announces that the Issuer successfully has executed the facilities agreement with, inter alios, certain lenders and is content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on the Redemption Date. The Condition has therefore been satisfied, and the Redemption is no longer conditional and will consequently occur on the Redemption Date. The redemption price, together with accrued and unpaid interest, will be paid to each person who is registered as owner of Notes in the debt register maintained by Euroclear Nordics AB at end of business as per the record date on 23 October 2026.

Further information regarding the Redemption can be found in the Issuer’s press release published on 6 October 2026.

For further information, please contact:

Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se

Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se

About Logent Group
Logent is a comprehensive and independent logistics partner, with a Nordic base and with global networks. We have a wide range of services and create value for our customers through guaranteed cost and quality improvements. Our services include Logistics Services such as Warehouse Management, Transport Management and Customs, Port and Combined Terminals, Staffing Services and Consulting Services. This means that Logent has grown to a turnover of about SEK 3 billion from the start in 2006 and employs approximately 3,000 people.